The trial medication won’t be available after the end of the trial, so participants won’t receive the trial medication when the trial finishes. If the trial shows a possible benefit from the sotagliflozin it is possible that sotagliflozin may become available for people with type 1 diabetes and heart failure.
We hope to finish the trial in late 2027 but it may take up to a year before we can publish the results. We’ll send participants a letter with the results once we have them. We’ll also let participants know if they received Sotagliflozin or the placebo at that point.